New! 2021 Knowledge Transfer Activities Accredited CSEM Education for You

Don't miss CSEM's new Knowledge Transfer Activities (KTAs) featuring case discussions and knowledge assessments, allowing you to claim Section 3 credits.

Free for CSEM and CPEG members! If you have not yet renewed your CSEM membership for 2021, kindly log in to renew here.

• April 14 at 7 p.m. ET — Growth Hormone Deficiency: New Options for Treatment & Long-Acting Therapies
• April 28 at 7 p.m. ET — Androgen Misuse and Abuse
• May 12 at 7 p.m. ET — Challenging Diabetes: Hyperglycemia in Cushing’s and Acromegaly

For more information and to register, click here.

CSEM is calling for nominations for President-Elect and one Director position on Council. Council members play an integral role in the growth and success of our organization. We're looking for enthusiastic and committed CSEM members with strong leadership abilities, and collaboration and communication skills. We want members who can help develop and deliver programs, and who are connected to the endocrine and metabolism community. Council advises the membership on matters related to governance, public policy, committee representation and strategic direction of the Society.

CSEM is recruiting Council members who collectively reflect the diversity of the endocrine medical community including constituent geographic areas, as well as all areas of endocrinology (i.e.: adult, pediatric academic, community and research), language, skills and experience.

Read the complete Call for Nominations, Roles and Responsibilities.

Nominate yourself or a colleague by May 24, 2021.

Save the Date — 2021 Professional Conference

With the continued uncertainty related to the COVID-19 pandemic, Diabetes Canada, CSEM, and the National Planning Committee have collectively decided to offer the 2021 Professional Conference as a virtual experience from November 24–26, 2021.

Registration is now open, click here!

The conference website will updated as more information becomes available.

CSEM has received questions from its members regarding the eligibility and safety of the COVID-19 vaccines and patients with endocrine conditions. Health Canada recommendations are changing rapidly. Recognizing there is little data to address groups excluded in the vaccine trials, a risk benefit assessment will need to be case-by-case and in consideration of national, provincial and local regulations.

CSEM supports equitable access to COVID-19 vaccines for individuals with endocrine conditions. Patients with type 1 diabetes, other autoimmune conditions, and immunocompromised health should have a risk/benefit discussion with their health care provider to make an informed decision. Some patients have multiple comorbidities that affect their vaccine status and patients may need to discuss with the relevant specialist(s).

Please see our statement for resources and references, including Diabetes Canada's statement.

December 21, 2020 Update:

CSEM is aware of a possible shortage of hydrocortisone (Cortef®) 10 mg. While Pfizer Canada’s stock of hydrocortisone (10-mg tablets) has been depleted, new supply is on track for mid-January, 2021. Additionally, it is anticipated that there is currently enough product at the community pharmacy level to cover the supply gap. Pfizer has issued the following notice to pharmacies informing them of the backlog and suggesting conservation of inventory when possible:

• English
• Français

medSask has a helpful conservation strategy document here: https://medsask.usask.ca/documents/drug-shortages-pdfs/hydrocortisone_shortage.pdf.

We will continue to remain in contact with Pfizer Canada and Health Canada's Drug Shortage Unit for regular updates and we will keep you keep you informed.